Neoplasms Clinical Trials in Denver, Colorado
4 studies are recruiting for neoplasms in Denver, Colorado right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.
Search these by distance from you
Studies now recruiting
-
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T-cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study. Participants who received at least o…
- Stage
- Phase 2
- Ages
- Any age
- Site
- Colorado Blood Cancer Institute, Denver, Colorado
- Locations
- 222 in total
- Run by
- Celgene
-
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
The main purpose of the master is to help the research sites and sponsor carry out several clinical trials more efficiently by providing a common research protocol. Individual clinical trials under this master protocol define drug/disease-specific research goals and activities to test them. New stu…
- Stage
- Phase 2
- Ages
- 1 to 39
- Site
- Children's Hospital of Colorado, Denver, Colorado
- Locations
- 72 in total
- Run by
- Eli Lilly and Company
-
A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)
The goal of this study is to assess the safety, tolerability, clinical activity and pharmacokinetics of Risvutatug rezetecan (Ris-Rez), also known as GSK5764227. The study will also see how the levels of Ris-Rez will change over time at different dose amounts when administered alone and in combinat…
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- GSK Investigational Site, Denver, Colorado
- Locations
- 67 in total
- Run by
- GlaxoSmithKline
-
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor
This is an open-label phase 1 study to determine the safety and tolebility of oral ABSK021 in patients with advanced solid tumor as well as the Recommended Phase 2 dose (RP2D) of oral ABSK021. Preliminary antitumor activity will also be assessed.
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- SCRI at HealthOne, Denver, Colorado
- Locations
- 17 in total
- Run by
- Abbisko Therapeutics Co, Ltd
How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.
What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.
Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.